Drug Type Synthetic peptide  | 
Synonyms JSM 6427  | 
Target  | 
Action antagonists  | 
Mechanism α5β1 antagonists(Integrin alpha-5/beta-1 antagonists)  | 
Therapeutic Areas  | 
Active Indication  | 
Inactive Indication  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
Regulation-  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Glycogen Storage Disease Type II | Phase 1 | United States   | 01 Sep 2007 | |
| Wet age-related macular degeneration | Phase 1 | United States   | 01 Sep 2007 | |
| Vitreoretinopathy, Proliferative | Preclinical | Germany   | 01 May 2007 | |
| Retinopathy of Prematurity | Preclinical | Germany   | 01 May 2006 | 
Phase 1  | - | gwiextuqzp(lzmaqoenqo) = jukhplywem vhgtddtgey (kkurzdylxz )  | -  | 01 Apr 2009  | |||
Phase 1  | - | eyorrkikzd(wlwpmtrvzt) = afnynvlqge ksptaxtmuu (xabebzfdif ) View more  | Positive  | 01 May 2008  | 






